TSHA
Taysha Gene Therapies, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.60
+0.54%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 462.59x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 4.71x
- Price / sales
- 332.67x
- Price / cash flow
- -13.80x
Enterprise value
- Enterprise value
- $1.4B
- EV / sales
- 259.77x
- EV / EBITDA
- -9.58x
- EV / EBIT
- -9.30x
- Market cap
- $1.8B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026